Benchsci announced completion of round B financing of US $22 million

Recently, benchsci, a biomedical company based in Canada, announced the completion of round B financing of 22 million US dollars to promote the development of new drugs using AI technology Benchsci's AI antibody selection technology can be completed in 30 seconds, compared to the 12 weeks usually needed to complete an antibody selection And by reducing inappropriate antibodies, it can save up to $3 million a year in consumable costs Its function supports searching by protein target and filtering by technology and 16 other experimental variables (including organism, tissue, cell type and disease) The AI driven platform established by benchsci provides reference materials in relevant scientific articles in digital form for researchers to verify their hypothesis By browsing a large number of scientific literature, and using the intelligent computer program based on supervised machine learning to retrieve every detail of antibody, so as to promote the birth of new discovery faster Benchsci's platform can standardize the test protocol, improve the efficiency of researchers, and prevent the incorrect test results due to the use of inappropriate antibodies Recently, the Swiss based biopharmaceutical company, stalicla, announced the completion of another US $8 million (chf7.7 million) financing, bringing its round a financing amount to US $18.4 million The fund will be used to promote stp1, a candidate drug for autism spectrum disorder (ASD), to enter phase 1b clinical trials, promote stp2, a second candidate drug, to enter preclinical research, and further expand its first depiv3 development platform focusing on neurodevelopmental disorder (NDD) Depiv3 platform integrates specific large-scale genetic, molecular, pharmacological and clinical data in the field to define patient subgroups and determine individualized treatment plans This is the first time to use this technology in the field of neurodevelopment, with the potential to change the direction of the profession With its depiv3 innovative biology AI platform, the company is recognized as a disruptive key player in the field of neurodevelopmental disorders reference material: